Scalable and Interoperable framework for a clinically diverse and generalizable sepsis Biorepository using Electronic alerts for Recruitment driven by Artificial Intelligence (short title: SIBER-AI)
使用人工智能驱动的招募电子警报的临床多样化和通用脓毒症生物库的可扩展和可互操作框架(简称:SIBER-AI)
基本信息
- 批准号:10576015
- 负责人:
- 金额:$ 18.32万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-01-01 至 2024-12-31
- 项目状态:已结题
- 来源:
- 关键词:Accident and Emergency departmentAcuteAlgorithmsAmbulancesAnimal ModelAntibioticsArtificial IntelligenceBiologicalCause of DeathCellsCessation of lifeCharacteristicsClinicalClinical ResearchCollectionConceptionsConsentCritical CareCritical IllnessCryopreserved CellDecision MakingDevelopmentDiagnosisDiseaseDisparityEarly treatmentElectronicsEnrollmentEnvironmentEthicsFamilyFunctional disorderHealthHospital MortalityHospitalsHourHumanImmune responseIndividualInfectionInformed ConsentIntegration Host FactorsIntensive Care UnitsInterventionLearningLength of StayMaintenanceManaged CareMeasuresMethodsModelingOrganOutcomePatient AdmissionPatient-Focused OutcomesPatientsPhenotypePhysiologicalPopulationPopulation HeterogeneityProceduresProcessResearchResearch PersonnelResearch SupportResourcesRiskSepsisSeveritiesSiteSourceSpecimenStandardizationSuspensionsTestingTimeTrustUnited StatesVariantVolatilizationacute carebiobankcell typeclinical translationcohortdesignexperiencegender disparityhospital careimprovedimproved outcomeinteroperabilitymortalitymortality riskmultimodalitymultiple omicsnovelnovel strategiesoperationpatient populationpersonalized managementprecision medicinepreservationracial disparityrecruitrepositoryscreeningseptic patientssurrogate decision makertargeted treatmenttreatment and outcomewardwearable sensor technology
项目摘要
PROJECT SUMMARY
Sepsis is a major health challenge worldwide that is associated with a significant risk of mortality. The key to
improved outcomes in sepsis is earlier treatment once diagnosed, with delays in therapy being associated with
worse outcomes. Sepsis is a heterogenous disease, and thus despite decades of research focused on various
aspects of sepsis, there still remains much to be learned about the underlying mechanisms that result in
differences in outcomes. The utilization of biorepositories gives investigators the opportunity to study different
mechanisms of disease; however, it is imperative that we collect biospecimens early on in disease and at
different time point in order to understand disease trajectory. Furthermore, there are opportunities within
critical care research to diversify the patient population enrolled in studies in order to investigate disparities that
occur in sepsis. Thus, the need to develop best practices and standard operation procedures are required
that may serve as templates for establishing scalable and generalizable sepsis biorepositories. This proposal
aims to 1) develop an integrated multi-modal clinical, physiologic, volatilomic, and multi-omic biorepository
profile driven by a semi-autonomous screening algorithm to enrich sepsis phenotypes; 2)design and test novel
methods of biospecimen collection among enriched sepsis populations in both ambulance and acute care
hospital environments ; and 3)develop novel approaches to biorepository consent that match the clinical
context of sepsis, maximize representativeness among patients, and enhance trust and engagement among
patients and surrogate decision-makers.
项目概要
脓毒症是世界范围内的一项重大健康挑战,与重大死亡风险相关。关键是
脓毒症预后的改善在于诊断后尽早治疗,治疗延迟与以下因素有关:
更糟糕的结果。脓毒症是一种异质性疾病,因此尽管数十年的研究集中于各种
脓毒症的各个方面,关于导致脓毒症的潜在机制仍有很多需要了解
结果的差异。生物样本库的利用使研究人员有机会研究不同的
疾病机制;然而,我们必须在疾病早期和早期收集生物样本
不同时间点以了解疾病轨迹。此外,内部还有机会
重症监护研究使参与研究的患者群体多样化,以调查以下差异:
发生于败血症。因此,需要制定最佳实践和标准操作程序
这可以作为建立可扩展和通用的脓毒症生物库的模板。这个提议
目标是 1) 开发一个集成的多模式临床、生理、挥发性和多组学生物样本库
由半自主筛选算法驱动的概况,以丰富脓毒症表型; 2)设计和测试新颖
在救护车和急症护理中丰富的脓毒症人群中采集生物样本的方法
医院环境; 3)开发符合临床的生物样本库同意新方法
败血症的背景下,最大限度地提高患者的代表性,并增强患者之间的信任和参与
患者和代理决策者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANNETTE M. ESPER其他文献
ANNETTE M. ESPER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANNETTE M. ESPER', 18)}}的其他基金
Biomarker and Metabolomic Investigations in ALI
ALI 的生物标志物和代谢组学研究
- 批准号:
8705005 - 财政年份:2013
- 资助金额:
$ 18.32万 - 项目类别:
Biomarker and Metabolomic Investigations in ALI
ALI 的生物标志物和代谢组学研究
- 批准号:
8466608 - 财政年份:2013
- 资助金额:
$ 18.32万 - 项目类别:
PPAR?? and Alveolar Macrophage Phenotype in Acute Lung Injury
过氧化物酶体受体??
- 批准号:
8190250 - 财政年份:2011
- 资助金额:
$ 18.32万 - 项目类别:
PPAR?? and Alveolar Macrophage Phenotype in Acute Lung Injury
过氧化物酶体受体??
- 批准号:
8298159 - 财政年份:2011
- 资助金额:
$ 18.32万 - 项目类别:
PPARγ and Alveolar Macrophage Phenotype in Acute Lung Injury
急性肺损伤中的 PPARγ 和肺泡巨噬细胞表型
- 批准号:
8879185 - 财政年份:2011
- 资助金额:
$ 18.32万 - 项目类别:
PPAR?? and Alveolar Macrophage Phenotype in Acute Lung Injury
过氧化物酶体受体??
- 批准号:
8689137 - 财政年份:2011
- 资助金额:
$ 18.32万 - 项目类别:
PPAR?? and Alveolar Macrophage Phenotype in Acute Lung Injury
过氧化物酶体受体??
- 批准号:
8500431 - 财政年份:2011
- 资助金额:
$ 18.32万 - 项目类别:
相似海外基金
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 18.32万 - 项目类别:
Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 18.32万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 18.32万 - 项目类别:
Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 18.32万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 18.32万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 18.32万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 18.32万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 18.32万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 18.32万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
- 批准号:
2244994 - 财政年份:2023
- 资助金额:
$ 18.32万 - 项目类别:
Standard Grant














{{item.name}}会员




